Acquired aplastic anemia in children

Pediatric Clinics of North America

Volumn 60, Issue 6, 2013, Pages 1311-1336

  Hartung, Helge D ^a   Olson, Timothy S ^a   Bessler, Monica ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acquired aplastic anemia; Bone marrow failure; Bone marrow transplant for severe aplastic anemia in children; Immune mediated aplastic anemia; Immunosuppressive therapy for severe aplastic anemia in children

Indexed keywords

ALEMTUZUMAB; ATOVAQUONE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; ELTROMBOPAG; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; LYMPHOGLOBULINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PENTAMIDINE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACQUIRED APLASTIC ANEMIA; ANEMIA; APLASTIC ANEMIA; BONE DISEASE; BONE MARROW BIOPSY; BONE MARROW DISEASE; BONE MARROW EXAMINATION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILDHOOD DISEASE; CHIMERA; COGNITIVE DEFECT; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DONOR SELECTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; EPISTAXIS; ERYTHROPOIESIS; FAMILY HISTORY; FANCONI ANEMIA; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL DISEASE; GENE MUTATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRANULOPOIESIS; GROWTH RETARDATION; HEMATOPOIESIS; HETEROZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MEGAKARYOPOIESIS; MENORRHAGIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCYTOPENIA; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL; PETECHIA; PSYCHOSOCIAL CARE; PUBERTY DISORDERS; RELAPSE; REVIEW; SECOND CANCER; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BRUISING; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROID DISEASE; TOOTH DISEASE; UNRELATED DONORS; VISUAL DISORDER; WHOLE BODY RADIATION;

EID: 84887614157     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2013.08.011     Document Type: Review

References (84)

1. Camitta B.M., Rappeport J.M., Parkman R., et al. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 1975, 45:355-363.
2. Bacigalupo A., Hows J., Gluckman E., et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988, 70:177-182.
3. Bessler M., Mason P., Link D., et al. Inherited bone marrow failure syndromes. Nathans and Oski's hematology of infancy and childhood 2013, W.B. Saunders Co, Philadelphia, in press. 8th edition. S.E. Orkin, D.G. Nathan, D. Ginsberg (Eds.).
4. Baumann I., Niemeyer C., Bennett J., et al. Childhood myelodysplastic syndrome. WHO classification of tumors of haematopoietic and lymphoid tissue 2008, vol. 2:104-107. International Agency for Research on Cancer, Lyon (France).
5. Baumann I., Fuhrer M., Behrendt S., et al. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria. Histopathology 2012, 61:10-17.
6. Montane E., Ibanez L., Vidal X., et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008, 93:518-523.
7. Kagan W.A., Ascensao J.A., Pahwa R.N., et al. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci USA 1976, 73:2890-2894.
8. Risitano A.M., Maciejewski J.P., Green S., et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004, 364:355-364.
9. Kordasti S., Marsh J., Al-Khan S., et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood 2012, 119:2033-2043.
10. Katagiri T., Sato-Otsubo A., Kashiwase K., et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 2011, 118:6601-6609.
11. Sutherland D.R., Kuek N., Davidson J., et al. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom 2007, 72:167-177.
12. Bessler M., Fehr J. Fc III receptors (FcRIII) on granulocytes: a specific and sensitive diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH). Eur J Haematol 1991, 47:179-184.
13. Sutton K.S., Shereck E.B., Nemecek E.R., et al. Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia. Pediatr Blood Cancer 2013, 60:455-460.
14. Du H.Y., Pumbo E., Ivanovich J., et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009, 113:309-316.
15. Kojima S., Nakao S., Young N., et al. The Third Consensus Conference on the treatment of aplastic anemia. Int J Hematol 2011, 93:832-837.
16. Babushok D.V., Xie H.M., Roth J.J., et al. Single Nucleotide Polymorphism Array Analysis of Bone Marrow Failure Patients Reveals Characteristic Patterns of Genetic Changes. Brit J Haematol 2013, in press.
17. Locasciulli A., Oneto R., Bacigalupo A., et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007, 92:11-18.
18. Valdez J.M., Scheinberg P., Nunez O., et al. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 2011, 52:726-735.
19. Marsh J.C., Bacigalupo A., Schrezenmeier H., et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012, 119:5391-5396.
20. Scheinberg P., Nunez O., Weinstein B., et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. NEngl J Med 2011, 365:430-438.
21. Neumann S., Krause S.W., Maschmeyer G., et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013, 92:433-442.
22. Quarello P., Saracco P., Giacchino M., et al. Epidemiology of infections in children with acquired aplastic anaemia: a retrospective multicenter study in Italy. Eur J Haematol 2012, 88:526-534.
23. Ohara A., Kojima S., Hamajima N., et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997, 90:1009-1013.
24. Quillen K., Wong E., Scheinberg P., et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009, 94:1661-1668.
25. Marsh J., Socie G., Tichelli A., et al. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol 2010, 150:377-379.
26. Jamuar S.S., Lai A.H. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol 2012, 3:299-307.
27. Samarasinghe S., Steward C., Hiwarkar P., et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012, 157:339-346.
28. Bacigalupo A., Marsh J.C. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 2013, 48:198-200.
29. Yoshimi A., Niemeyer C.M., Fuhrer M.M., et al. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. Blood 2013, 121:860-861.
30. Armand P., Antin J.H. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant 2007, 13:505-516.
31. Bunin N., Leahey A., Kamani N., et al. Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. JPediatr Hematol Oncol 1996, 18:68-71.
32. Kahl C., Leisenring W., Deeg H.J., et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005, 130:747-751.
33. Ades L., Mary J.Y., Robin M., et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004, 103:2490-2497.
34. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.
35. Pulsipher M.A., Young N.S., Tolar J., et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2011, 17:291-299.
36. George B., Mathews V., Viswabandya A., et al. Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. Pediatr Transplant 2008, 12:14-19.
37. Resnick I.B., Aker M., Shapira M.Y., et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol 2006, 133:649-654.
38. Buchbinder D., Nugent D.J., Brazauskas R., et al. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2012, 18:1776-1784.
39. Sanders J.E., Woolfrey A.E., Carpenter P.A., et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011, 118:1421-1428.
40. Konopacki J., Porcher R., Robin M., et al. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica 2012, 97:710-716.
41. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007, 110:1397-1400.
42. Myers K.C., Davies S.M. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant 2009, 15:279-292.
43. Young N.S., Bacigalupo A., Marsh J.C. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant 2010, 16:S119-S125.
44. Ostronoff F., Ostronoff M., Souto-Maior A.P., et al. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 2009, 23:33-38.
45. Yagasaki H., Kojima S., Yabe H., et al. Tacrolimus/methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant 2009, 15:1603-1608.
46. Lawler M., McCann S.R., Marsh J.C., et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol 2009, 144:933-945.
47. Maury S., Bacigalupo A., Anderlini P., et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009, 94:1312-1315.
48. Yagasaki H., Takahashi Y., Hama A., et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant 2010, 45:1508-1513.
49. Peffault de Latour R., Purtill D., Ruggeri A., et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2011, 17:78-85.
50. Buchbinder D., Hsieh L., Puthenveetil G., et al. Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia. Pediatr Transplant 2013, 17:E104-E107.
51. Im H.J., Koh K.N., Choi E.S., et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2013, 19:754-759.
52. Wang H., Yan H., Wang Z., et al. Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia. Pediatrics 2012, 129:e1612-e1615.
53. Eapen M., Horowitz M.M. Alternative donor transplantation for aplastic anemia. Hematology Am Soc Hematol Educ Program 2010, 2010:43-46.
54. Bunin N., Aplenc R., Iannone R., et al. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion. Bone Marrow Transplant 2005, 35:369-373.
55. Bacigalupo A., Locatelli F., Lanino E., et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005, 36:947-950.
56. Frickhofen N., Heimpel H., Kaltwasser J.P., et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003, 101:1236-1242.
57. Samarasinghe S., Webb D.K. How I manage aplastic anaemia in children. Br J Haematol 2012, 157:26-40.
58. Saracco P., Quarello P., Iori A.P., et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008, 140:197-205.
59. Dufour C., Svahn J., Bacigalupo A. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant 2013, 48:174-177.
60. Fuhrer M., Rampf U., Baumann I., et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005, 106:2102-2104.
61. Tichelli A., Schrezenmeier H., Socie G., et al. Arandomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011, 117:4434-4441.
62. Alsultan A., Goldenberg N.A., Kaiser N., et al. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer 2009, 52:626-630.
63. Kamio T., Ito E., Ohara A., et al. Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group. Haematologica 2011, 96:814-819.
64. Brodsky R.A., Chen A.R., Dorr D., et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010, 115:2136-2141.
65. Olnes M.J., Scheinberg P., Calvo K.R., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. NEngl J Med 2012, 367:11-19.
66. Nishio N., Yagasaki H., Takahashi Y., et al. Natural history of transfusion-independent non-severe aplastic anemia in children. Int J Hematol 2009, 89:409-413.
67. Howard S.C., Naidu P.E., Hu X.J., et al. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer 2004, 43:545-551.
68. Brock K., Goldenberg N., Graham D.K., et al. Moderate aplastic anemia in children: preliminary outcomes for treatment versus observation from a single-institutional experience. JPediatr Hematol Oncol 2013, 35:148-152.
69. Marsh J., Schrezenmeier H., Marin P., et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999, 93:2191-2195.
70. Nimer S.D., Ireland P., Meshkinpour A., et al. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994, 84:923-927.
71. Sugimori C., Yamazaki H., Feng X., et al. Roles of DRB1 *1501 and DRB1 **1502 in the pathogenesis of aplastic anemia. Exp Hematol 2007, 35:13-20.
72. Fuhrer M., Durner J., Brunnler G., et al. HLA association is different in children and adults with severe acquired aplastic anemia. Pediatr Blood Cancer 2007, 48:186-191.
73. Yoshida N., Yagasaki H., Takahashi Y., et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol 2008, 142:427-435.
74. Scheinberg P., Wu C.O., Nunez O., et al. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. JPediatr 2008, 153:814-819.
75. Kosaka Y., Yagasaki H., Sano K., et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008, 111:1054-1059.
76. Scheinberg P., Nunez O., Young N.S. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006, 133:622-627.
77. Gupta V., Brooker C., Tooze J.A., et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol 2006, 134:95-99.
78. Afable M.G., Wlodarski M., Makishima H., et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 2011, 117:6876-6884.
79. Socie G., Mary J.Y., Schrezenmeier H., et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007, 109:2794-2796.
80. Niemeyer C.M., Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol 2008, 45:60-70.
81. Stalder M.P., Rovo A., Halter J., et al. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol 2009, 88:659-665.
82. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. NEngl J Med 1993, 329:1152-1157.
83. Chapuis B., Von Fliedner V.E., Jeannet M., et al. Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol 1986, 63:51-57.
84. Babushok D.V., Li Y., Roth J.J., et al. Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: independent cohort and meta-analysis of 609 patients. Am J Hematol 2013, 88(10):862-867.